http://www.biocentury.com/rss/biotech-pharma-newsThe Bernstein Report on BioBusiness feedsen-US Copyright 2013 BioCentury, Inc.RSS Generatorhttp://www.biocentury.com/Data/NewsCenter2/Images/biotech-pharma-news/CoverStory.gifhttp://www.biocentury.com/rss/biotech-pharma-newshttp://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-17/why-buysiders-bankers-think-2013-ipo-window-can-continue-a1http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-17/why-buysiders-bankers-think-2013-ipo-window-can-continue-a1Cover StoryBankers and buysiders agree: As long as quality companies remain on offer and valuations are fair, biotech IPOs will keep thriving as large cap performance and fund inflows mean investors have cash for new stories.Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/analysts/2013-06-17/analyst-picks-and-changes-07http://www.biocentury.com/biotech-pharma-news/analysts/2013-06-17/analyst-picks-and-changes-07Analyst Picks & ChangesAnalyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/14 cls Addex Therapeutics Ltd. (SIX:ADXN) Wedbush Christopher Marai Downgrade Neutral (from outperform) 18% CHF3.98 Marai also …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-17/level-headed-enthusiasm-table-ipo-performance-01http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-17/level-headed-enthusiasm-table-ipo-performance-01Cover StoryLevel-headed enthusiasm IPO performance Thus far in 2013, 16 biotechs have raised $965 million from IPOs. Ten were completed in the second quarter for $636.6 million. The group is up a median of 26% from their …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-17/level-headed-enthusiasm-table-ipo-queue-02http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-17/level-headed-enthusiasm-table-ipo-queue-02Cover StoryLevel-headed enthusiasm IPO queue At least 20 companies have proposed IPOs, including 14 announced since the start of April. Unless noted, the companies are seeking to list on NASDAQ. Most recent filing at top. (A) …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-17/autifony-aims-to-improve-auditory-processing-prevent-persistent-hearing-damage-a12http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-17/autifony-aims-to-improve-auditory-processing-prevent-persistent-hearing-damage-a12Emerging Company ProfileAutifony is developing modulators of an ion channel to improve the brain's auditory processing and mitigate permanent hearing loss or tinnitus associated with cochlear damage.Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-17/autifony-sense-and-sensitivity-sidebar-autifony-therapeutics-ltd-corporate-profile-05http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-17/autifony-sense-and-sensitivity-sidebar-autifony-therapeutics-ltd-corporate-profile-05Emerging Company ProfileAutifony: Sense and sensitivity Autifony Therapeutics Ltd. London, U.K. Technology: Compounds targeting Kv3 voltage-gated ion channels Disease focus: Neurology Clinical status: Phase I Founded: 2011 by Charles …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-17/trino-has-new-class-of-anti-inflammatory-compounds-for-ulcerative-colitis-a11http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-17/trino-has-new-class-of-anti-inflammatory-compounds-for-ulcerative-colitis-a11Emerging Company ProfileTrino spun out of Trinity College Dublin with a portfolio of novel anti-inflammatory compounds that have shown potential in preclinical models of ulcerative colitis.Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-17/trino-planting-gi-health-sidebar-trino-therapeutics-ltd-corporate-profile-04http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-17/trino-planting-gi-health-sidebar-trino-therapeutics-ltd-corporate-profile-04Emerging Company ProfileTrino: Planting GI health Trino Therapeutics Ltd. Dublin, Ireland Technology: Dimeric indane-based scaffold molecules derived from a Taiwanese fern Disease focus: Inflammation, autoimmune, gastrointestinal …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/biotech-investor-banker-and-analyst-personnel-changes-a17fhttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/biotech-investor-banker-and-analyst-personnel-changes-a17fFinanceEbb & Flow LP tracks Janine Guillot stepped down as chief operating investment officer at the California Public Employees' Retirement System (CalPERS), effective May 24. Carol Moody was named interim COIO by CalPERS…Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/ebb-and-flow-figure-money-raised-in-2013-06http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/ebb-and-flow-figure-money-raised-in-2013-06FinanceLiving the dream Money Raised in 2013 Last week, the biotech industry raised $532 million, bringing to $12.6 billion the total raised year-to-date. In 2012, a total of $36.2 billion was raised, including $19.9 …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/huge-demand-for-peptidream-shares-despite-macroeconomic-concerns-in-japan-a17ahttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/huge-demand-for-peptidream-shares-despite-macroeconomic-concerns-in-japan-a17aFinanceEbb & Flow Living the dream PeptiDream Inc. (Tokyo:4587) jumped over 400% in its first week of trading, but due to rules on daily price limits, there's no telling what investors are really willing to pay for the …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/japanese-investors-hope-prisms-expansion-beyond-cancer-will-double-valuation-a17bhttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/japanese-investors-hope-prisms-expansion-beyond-cancer-will-double-valuation-a17bFinanceEbb & Flow Broader spectrum Prism Pharma Co. Ltd. plans to use the $15 million it raised in a series C round last week to expand the Japanese company's focus beyond cancer and beef up its valuation. New investor …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/level-headed-enthusiasm-table-ipo-performance-01http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/level-headed-enthusiasm-table-ipo-performance-01FinanceLevel-headed enthusiasm IPO performance Thus far in 2013, 16 biotechs have raised $965 million from IPOs. Ten were completed in the second quarter for $636.6 million. The group is up a median of 26% from their …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/level-headed-enthusiasm-table-ipo-queue-02http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/level-headed-enthusiasm-table-ipo-queue-02FinanceLevel-headed enthusiasm IPO queue At least 20 companies have proposed IPOs, including 14 announced since the start of April. Unless noted, the companies are seeking to list on NASDAQ. Most recent filing at top. (A) …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/myriad-shares-jump-then-slump-on-fast-moving-competition-following-scotus-a17chttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/myriad-shares-jump-then-slump-on-fast-moving-competition-following-scotus-a17cFinanceEbb & Flow Breaching Myriad's walls Myriad Genetics Inc. (NASDAQ:MYGN) jumped more than 10% in intraday trading Thursday as the company claimed victory on a U.S. Supreme Court ruling allowing cDNA patents. But the …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/pharma-deals-in-hand-qb3-aims-for-new-mission-bay-fund-more-california-money-a17ehttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/pharma-deals-in-hand-qb3-aims-for-new-mission-bay-fund-more-california-money-a17eFinanceEbb & Flow Funding QB3 The California Institute for Quantitative Biosciences (QB3) and venture affiliate Mission Bay Capital hope to become self-sustaining, but they aren't there yet. Mission Bay aims to raise over…Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/regulatory-clinical-and-other-milestones-a17ghttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/regulatory-clinical-and-other-milestones-a17gFinanceEbb & Flow Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) was up $0.56 (12%) to $5.05 last week after the U.K.'s NICE issued draft guidance recommending Iluvien fluocinolone acetonide intravitreal implant…Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/theravance-investors-ponder-what-happens-if-elan-royalty-deal-falls-through-a17dhttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/theravance-investors-ponder-what-happens-if-elan-royalty-deal-falls-through-a17dFinanceEbb & Flow Easy come, easy go Theravance Inc. (NASDAQ:THRX) treaded water Friday as investors digested the possibility that the company's proposed sale of royalties to Elan Corp. plc (NYSE:ELN) may get scuttled by …Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/why-buysiders-bankers-think-2013-ipo-window-can-continue-a1http://www.biocentury.com/biotech-pharma-news/finance/2013-06-17/why-buysiders-bankers-think-2013-ipo-window-can-continue-a1FinanceBankers and buysiders agree: As long as quality companies remain on offer and valuations are fair, biotech IPOs will keep thriving as large cap performance and fund inflows mean investors have cash for new stories.Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/politics/2013-06-17/scotus-myriad-protects-biotech-patenting-but-leaves-important-gray-areas-a13http://www.biocentury.com/biotech-pharma-news/politics/2013-06-17/scotus-myriad-protects-biotech-patenting-but-leaves-important-gray-areas-a13Politics and PolicyThe Supreme Court's Myriad ruling looks to be a net win for biotech companies now. But it did not draw a bright line to determine how close a potential invention can come to a naturally occurring phenomenon.Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-17/astellas-new-randd-strategy-focused-on-growing-preclinical-pipeline-a6http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-17/astellas-new-randd-strategy-focused-on-growing-preclinical-pipeline-a6StrategyWith a stocked late-stage pipeline, Astellas has turned its attention to growing its early-stage pipeline with a focus on external partnerships over traditional bricks-and-mortar R&D.Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-17/externalizing-astellas-figure-building-the-astellas-pipeline-03http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-17/externalizing-astellas-figure-building-the-astellas-pipeline-03StrategyExternalizing Astellas Building the Astellas pipeline Astellas Pharma Inc. (Tokyo:4503) has relied heavily on in-licensing and acquisitions to stock its clinical-stage pipeline, with 15 of its 22 Phase III/…Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-17/jv-gives-astellas-programs-in-core-areas-amgen-commercial-presence-in-japan-a10http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-17/jv-gives-astellas-programs-in-core-areas-amgen-commercial-presence-in-japan-a10StrategyAmgen has had a development foothold in Japan for decades, but its new JV with Astellas will give the biotech its first commercial presence in the country.Mon, 17 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-10/avandias-real-lesson-how-to-use-melange-of-data-in-real-world-risk-management-a1http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-10/avandias-real-lesson-how-to-use-melange-of-data-in-real-world-risk-management-a1Cover StoryThe latest panel review of the diabetes drug could provide insight into how FDA will make benefit-risk decisions in the postmarket as it is increasingly faced with a similar melange of real-world and clinical data.Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/analysts/2013-06-10/analyst-picks-and-changes-06http://www.biocentury.com/biotech-pharma-news/analysts/2013-06-10/analyst-picks-and-changes-06Analyst Picks & ChangesAnalyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/7 cls Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) Leerink Joseph Schwartz Upgrade Outperform (from market perform) 7% $15.97 …Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-10/avandias-real-lesson-table-record-replay-01http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-10/avandias-real-lesson-table-record-replay-01Cover StoryAvandia's real lesson RECORD replay At last week's joint meeting of the Endocrinologic and Metabolic Drugs and the Drug Safety and Risk Management advisory committees on Avandia rosiglitazone, the returning panel …Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-10/onl-therapeutics-eyeing-fas-sidebar-onl-therapeutics-llc-corporate-profile-03http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-10/onl-therapeutics-eyeing-fas-sidebar-onl-therapeutics-llc-corporate-profile-03Emerging Company ProfileONL Therapeutics: Eyeing Fas ONL Therapeutics LLC Ann Arbor, Mich. Technology: Peptide antagonist of Fas-mediated apoptosis for ophthalmic use Disease focus: Ophthalmic Clinical status: Preclinical Founded: 2011…Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-10/onls-fas-antagonist-inhibits-universal-death-pathway-in-retinal-pathologies-a17http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-10/onls-fas-antagonist-inhibits-universal-death-pathway-in-retinal-pathologies-a17Emerging Company ProfileONL's Fas antagonist may be the first pharmacotherapy to prevent vision loss in non-exudative retinal detachment. It could complement existing ophthalmic therapies by blocking the sole pathway of photoreceptor deathMon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/clovis-gains-more-on-phase-i-data-than-it-lost-on-one-pivotal-failure-a18ahttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/clovis-gains-more-on-phase-i-data-than-it-lost-on-one-pivotal-failure-a18aFinanceFigure: Money Raised in 2013 Table: ASCO movers After presenting early Phase I data at ASCO, Clovis Oncology Inc. (NASDAQ:CLVS) got back more …Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/ebb-and-flow-figure-money-raised-in-2013-04http://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/ebb-and-flow-figure-money-raised-in-2013-04FinanceEbb & Flow Money Raised in 2013 Last week, the biotech industry raised $611 million, bringing to $12.1 billion the total raised year-to-date. In 2012, a total of $36.2 billion was raised, including $19.9 billion in …Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/ebb-and-flow-table-asco-movers-05http://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/ebb-and-flow-table-asco-movers-05FinanceEbb & Flow ASCO movers At least eight biotechs gained or lost more than 10% last week after presenting at the American Society of Clinical Oncology meeting in Chicago. Clovis Oncology Inc. (NASDAQ:CLVS) topped the …Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/peptidream-launches-into-public-trading-as-japan-biotech-bubble-quivers----a18bhttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/peptidream-launches-into-public-trading-as-japan-biotech-bubble-quivers----a18bFinanceEbb & Flow Tip-toeing on the bubble PeptiDream Inc. could be facing choppy waters as it makes its public debut this Tuesday in Japan. Last week, the macrocycle company raised ¥5.3 billion ($52.4 million) through …Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/regulatory-clinical-and-other-milestones-a18ehttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/regulatory-clinical-and-other-milestones-a18eFinanceEbb & Flow Regulatory milestones AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) gained $0.24 to $19.79 on Friday after partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted a Type II variation application to EMA to…Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/sosei-launching-japan-seed-fund-to-access-regenerative-medicine-technologies-a18chttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/sosei-launching-japan-seed-fund-to-access-regenerative-medicine-technologies-a18cFinanceEbb & Flow Regenerative reservoir Sosei Group Corp. (Tokyo:4565) is launching a ¥2 billion ($19.9 million) seed fund to invest in Japanese regenerative medicine companies that will give the portfolio companies time …Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/why-europes-prosensa-cardio3-chose-different-sides-of-atlantic-for-ipos-a18dhttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-10/why-europes-prosensa-cardio3-chose-different-sides-of-atlantic-for-ipos-a18dFinanceEbb & Flow Floating across the pond A booming U.S. IPO market has some private European biotechs thinking about whether to make the leap over the pond. The decisions of two companies show that a U.S. listing may be …Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/products/2013-06-10/immune-checkpoint-inhibitors-oncolytic-virus-best-yervoy-in-melanoma-at-asco-a11http://www.biocentury.com/biotech-pharma-news/products/2013-06-10/immune-checkpoint-inhibitors-oncolytic-virus-best-yervoy-in-melanoma-at-asco-a11Product Discovery & DevelopmentPhase I data presented at ASCO suggest the next wave of immunotherapies in melanoma could generate better tumor responses than ipilimumab with the same or better safety profile.Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/products/2013-06-10/post-yervoy-landscape-table-checking-up-on-melanoma-02http://www.biocentury.com/biotech-pharma-news/products/2013-06-10/post-yervoy-landscape-table-checking-up-on-melanoma-02Product Discovery & DevelopmentPost-Yervoy landscape Checking up on melanoma Phase I proof-of-concept data presented at last week's American Society of Clinical Oncology meeting in Chicago suggest the next wave of immunotherapies in melanoma …Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/products/2013-06-10/potency-key-as-obinutuzumab-arzerra-try-to-best-rituxan-in-cll-a14http://www.biocentury.com/biotech-pharma-news/products/2013-06-10/potency-key-as-obinutuzumab-arzerra-try-to-best-rituxan-in-cll-a14Product Discovery & DevelopmentThe cohort of anti-CD20 monoclonals seeking to improve upon Rituxan is reporting its first pivotal trial results in elderly and unfit CLL patients awaiting enhancements upon chlorambucilMon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/regulation/2013-06-10/avandias-real-lesson-how-to-use-melange-of-data-in-real-world-risk-management-a1http://www.biocentury.com/biotech-pharma-news/regulation/2013-06-10/avandias-real-lesson-how-to-use-melange-of-data-in-real-world-risk-management-a1RegulationThe latest panel review of the diabetes drug could provide insight into how FDA will make benefit-risk decisions in the postmarket as it is increasingly faced with a similar melange of real-world and clinical data.Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/regulation/2013-06-10/avandias-real-lesson-table-record-replay-01http://www.biocentury.com/biotech-pharma-news/regulation/2013-06-10/avandias-real-lesson-table-record-replay-01RegulationAvandia's real lesson RECORD replay At last week's joint meeting of the Endocrinologic and Metabolic Drugs and the Drug Safety and Risk Management advisory committees on Avandia rosiglitazone, the returning panel …Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-10/merck-serono-quintiles-team-up-to-reduce-time-cost-of-phase-i-iv-trials-a9http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-10/merck-serono-quintiles-team-up-to-reduce-time-cost-of-phase-i-iv-trials-a9StrategyMerck Serono is bringing Quintiles to the table for clinical strategy, protocol design and execution of the specialty pharma's Phase I-IV trials. The goal is shorter, cheaper trials with higher success rates.Mon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-10/pbm-catamaran-believes-oral-ms-drugs-could-improve-adherence-likes-pricing-a7http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-10/pbm-catamaran-believes-oral-ms-drugs-could-improve-adherence-likes-pricing-a7StrategyAt least one PBM believes oral MS drugs have entered the market at the right price relative to their injectible competition; long-term outcomes data could boost the orals on formulariesMon, 10 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-03/looking-beyond-the-first-duchenne-muscular-dystrophy-therapies-a1http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-03/looking-beyond-the-first-duchenne-muscular-dystrophy-therapies-a1Cover StoryAs late-stage DMD companies approach the finish line, researchers already are looking toward a cocktail they think will ultimately be necessary to treat the majority of patients.Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/analysts/2013-06-03/analyst-picks-and-changes-05http://www.biocentury.com/biotech-pharma-news/analysts/2013-06-03/analyst-picks-and-changes-05Analyst Picks & ChangesAnalyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/31 cls Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) Canaccord Salveen Richter Price target Buy 21% $72.83 JPMorgan Cory Kasimov …Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-03/the-dmd-landscape-table-dmd-pipeline-01http://www.biocentury.com/biotech-pharma-news/coverstory/2013-06-03/the-dmd-landscape-table-dmd-pipeline-01Cover StoryThe DMD landscape DMD pipeline At least 10 compounds are in clinical development for Duchenne muscular dystrophy (DMD). The therapies include compounds that target the dysfunctional or absent dystrophin gene, as …Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-03/cyteir-stopping-shape-shifters-sidebar-cyteir-therapeutics-inc-corporate-profile-03http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-03/cyteir-stopping-shape-shifters-sidebar-cyteir-therapeutics-inc-corporate-profile-03Emerging Company ProfileCyteir: Stopping shape-shifters Cyteir Therapeutics Inc. Hinsdale, Ill. Technology: Small molecules targeting DNA repair Disease focus: Cancer Clinical status: Preclinical Founded: 2012 by Kevin Mills, Tim …Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-03/cyteir-targets-dna-repair-enzyme-critical-for-chronic-lymphocytic-leukemias-a10http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-06-03/cyteir-targets-dna-repair-enzyme-critical-for-chronic-lymphocytic-leukemias-a10Emerging Company ProfileCyteir is developing small molecule inhibitors of RAD51, a DNA repair enzyme used by many chronic lymphocytic leukemias.Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/biotech-investor-banker-and-analyst-personnel-changes-a16dhttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/biotech-investor-banker-and-analyst-personnel-changes-a16dFinanceEbb & Flow Analyst tracks Catherine Arnold joined Wellington Management as a global industry analyst. She was a managing director and senior analyst for U.S. pharmaceuticals at Credit Suisse. Andrew Fein joined H.C…Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/ebb-and-flow-figure-money-raised-in-2013-04http://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/ebb-and-flow-figure-money-raised-in-2013-04FinanceOkairos is OK Money Raised in 2013 Last week, the biotech industry raised $197 million, bringing to $11.5 billion the total raised year-to-date. In 2012, a total of $36.2 billion was raised, including $19.9 billion …Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/novo-as-using-strong-cash-flow-to-invest-in-mature-companies-like-xellia-a15http://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/novo-as-using-strong-cash-flow-to-invest-in-mature-companies-like-xellia-a15FinanceLacking an abundance of worthwhile venture deals, Novo A/S is putting its cash flow to work by expanding its growth equity investments in mature life science companies like Xellia.Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/ophthotech-secures-175m-may-not-be-enough-for-fovista-phase-iii-in-amd-a16bhttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/ophthotech-secures-175m-may-not-be-enough-for-fovista-phase-iii-in-amd-a16bFinanceEbb & Flow Part-way financing Ophthotech Corp. did two deals last week that could bring in $175 million, but the biotech expects it still will need additional capital to complete a Phase III trial of Fovista for wet…Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/regulatory-clinical-and-other-milestones-a16ehttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/regulatory-clinical-and-other-milestones-a16eFinanceEbb & Flow Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $12.74 (21%) to $72.83 last week after at least two analysts raised their price targets on the stock and EMA's CHMP backed approval…Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/vcs-make-10x-plus-on-vaccine-maker-okairos-6-year-journey-from-merck-to-gsk-a16ahttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/vcs-make-10x-plus-on-vaccine-maker-okairos-6-year-journey-from-merck-to-gsk-a16aFinanceEbb & Flow Okairos is OK Figure: Money Raised in 2013 Okairos AG rewarded investors who helped spin the T cell vaccine developer out of Merck & Co Inc. (NYSE:MRK) in 2007. The €250 million ($323 million) that …Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/vcs-would-have-made-a-bit-more-if-azs-bid-for-omthera-had-come-pre-ipo-a16chttp://www.biocentury.com/biotech-pharma-news/finance/2013-06-03/vcs-would-have-made-a-bit-more-if-azs-bid-for-omthera-had-come-pre-ipo-a16cFinanceEbb & Flow Money on the table Sofinnova Partners and NEA turned a tidy profit from last week's sale of Omthera Pharmaceuticals Inc. (NASDAQ:OMTH) to AstraZeneca plc (LSE:AZN; NYSE:AZN), though it might have been …Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/products/2013-06-03/looking-beyond-the-first-duchenne-muscular-dystrophy-therapies-a1http://www.biocentury.com/biotech-pharma-news/products/2013-06-03/looking-beyond-the-first-duchenne-muscular-dystrophy-therapies-a1Product Discovery & DevelopmentAs late-stage DMD companies approach the finish line, researchers already are looking toward a cocktail they think will ultimately be necessary to treat the majority of patients.Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/products/2013-06-03/the-dmd-landscape-table-dmd-pipeline-01http://www.biocentury.com/biotech-pharma-news/products/2013-06-03/the-dmd-landscape-table-dmd-pipeline-01Product Discovery & DevelopmentThe DMD landscape DMD pipeline At least 10 compounds are in clinical development for Duchenne muscular dystrophy (DMD). The therapies include compounds that target the dysfunctional or absent dystrophin gene, as …Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/regulation/2013-06-03/phrma-bio-creating-pdufa-v-tracking-database-a11http://www.biocentury.com/biotech-pharma-news/regulation/2013-06-03/phrma-bio-creating-pdufa-v-tracking-database-a11RegulationPhRMA and BIO are launching an effort to meticulously document the actual performance of PDUFA V's new review processes for NMEs -- and provide hard data for the PDUFA VI negotiations.Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/regulation/2013-06-03/why-fda-might-back-lower-starting-dose-of-mercks-suvorexant-for-insomnia-a13http://www.biocentury.com/biotech-pharma-news/regulation/2013-06-03/why-fda-might-back-lower-starting-dose-of-mercks-suvorexant-for-insomnia-a13RegulationWith an advisory committee's blessing, FDA appears poised to approve a lower -- and possibly safer -- dose of insomnia candidate suvorexant than Merck tested in Phase III.Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-03/how-japans-taiho-plans-to-expand-in-west-using-late-stage-cancer-compounds-a7http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-03/how-japans-taiho-plans-to-expand-in-west-using-late-stage-cancer-compounds-a7StrategyTaiho has embarked on a five-year plan to expand into Western markets using two chemotherapeutics as late-stage beachheads for its early stage pipeline of innovative small molecules.Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-03/taiho-goes-global-table-taihos-cancer-pipeline-02http://www.biocentury.com/biotech-pharma-news/strategy/2013-06-03/taiho-goes-global-table-taihos-cancer-pipeline-02StrategyTaiho goes global Taiho's cancer pipeline Taiho Pharmaceutical Co. Ltd.'s cancer pipeline consists of both chemotherapeutics and targeted therapies, along with programs in-licensed specifically for the Japanese and/…Mon, 03 Jun 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/european-investors-demand-biotechs-focus-on-product-reimbursement-profile-a1http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/european-investors-demand-biotechs-focus-on-product-reimbursement-profile-a1Cover StoryBioCentury's 11th European Iceberg survey finds investors pushing companies to adapt to the new healthcare ecosystem by preparing assets to meet the needs of both payers and regulators.Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/analysts/2013-05-27/analyst-picks-and-changes-14http://www.biocentury.com/biotech-pharma-news/analysts/2013-05-27/analyst-picks-and-changes-14Analyst Picks & ChangesAnalyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/24 cls Cubist Pharmaceuticals Inc. (NASDAQ:CBST) Jefferies Eun Yang Price target Buy 12% $55.49 RBC Capital Markets Adnan Butt …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/demand-disequilibrium-figure-clinical-rationing-06http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/demand-disequilibrium-figure-clinical-rationing-06Cover StoryDemand disequilibrium Clinical rationing Europe's private and public biotechs in the clinic both raised more money in 2012 vs. 2011. Of the $1.2 billion raised by private biotechs in 2012, $806.3 million, or 66%, …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/demand-disequilibrium-figure-private-demand-09http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/demand-disequilibrium-figure-private-demand-09Cover StoryDemand disequilibrium Private demand Private European biotechs in the clinic and beyond will need an estimated $4.54 billion to support operations to the end of 2015, compared with a three-year estimate of $4.59 …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/demand-disequilibrium-figure-public-demand-08http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/demand-disequilibrium-figure-public-demand-08Cover StoryDemand disequilibrium Public demand Public European biotechs in the clinic and beyond, but have not yet reached a profit, will need an estimated $906.5 million to support operations to the end of 2015. This compares…Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/demand-disequilibrium-table-new-eu-funds-07http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/demand-disequilibrium-table-new-eu-funds-07Cover StoryDemand disequilibrium New EU funds Since the start of 2012, at least 19 funds with a focus on life science investing in Europe have raised a total of more than $2.5 billion. (A) Fund was closed in 2010, but was re-…Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/results-of-biocenturys-11th-survey-of-funding-needs-for-european-biotechs-a8http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/results-of-biocenturys-11th-survey-of-funding-needs-for-european-biotechs-a8Cover StoryBioCentury's 11th European Iceberg survey sees funding demand continue to fall for a shrinking number public clinical-stage biotechs in Europe, while underlying demand by a growing cadre of venture plays continues to …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/value-reality-check-figure-capital-rationing-04http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/value-reality-check-figure-capital-rationing-04Cover StoryValue reality check Capital rationing The average venture raised per European company was $12.8 million in 2012 vs. $11.8 million in 2011. The 2012 number includes a $150 million series B round by NovImmune S.A. …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/value-reality-check-figure-eu-vs-us-private-raised-03http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/value-reality-check-figure-eu-vs-us-private-raised-03Cover StoryValue reality check EU vs. U.S. private raised Private European biotechs raised $1.2 billion in 2012, the same amount as in 2011. In the U.S., private companies saw a 28% increase in venture money raised to $4.7 …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/value-reality-check-figure-eu-vs-us-public-raised-01http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/value-reality-check-figure-eu-vs-us-public-raised-01Cover StoryValue reality check EU vs. U.S. public raised Excluding debt, the top figure shows public biotechs in Europe increased their fundraising by 24% to $1.2 billion from 2011 vs. a 35% increase in the U.S. to $8.3 …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/value-reality-check-figure-europes-total-demand-05http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/value-reality-check-figure-europes-total-demand-05Cover StoryDemand disequilibrium Europe's total demand BioCentury projects that private and public European biotech companies with compounds in the clinic and beyond will need $5.5 billion over the next three years to keep …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/value-reality-check-figure-global-competition-for-capital-02http://www.biocentury.com/biotech-pharma-news/coverstory/2013-05-27/value-reality-check-figure-global-competition-for-capital-02Cover StoryValue reality check Global competition for capital The total money raised by European and U.S. biotechs declined in 2012, as 2011 and 2010 were bulked up by a series of large debt deals. The funding figure actually …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-05-27/calypso-fistula-fix-sidebar-calypso-biotech-sa-corporate-profile-10http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-05-27/calypso-fistula-fix-sidebar-calypso-biotech-sa-corporate-profile-10Emerging Company ProfileCalypso: Fistula fix Calypso Biotech S.A. Geneva, Switzerland Technology: mAbs to treat gastrointestinal-related autoimmune diseases Disease focus: Autoimmune Clinical status: Preclinical Founded: 2013 by …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-05-27/merck-serono-spinout-calypso-developing-mabs-to-treat-crohns-celiac-a16http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-05-27/merck-serono-spinout-calypso-developing-mabs-to-treat-crohns-celiac-a16Emerging Company ProfileCalypso expects its antibodies will be able to treat the underlying inflammation in patients with Crohn's disease, as well as the fibrotic complications that marketed therapies don't address.Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-05-27/numab-hopes-anti-t-cell-mab-will-best-anti-th17-drugs-in-autoimmune-disorders-a17http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-05-27/numab-hopes-anti-t-cell-mab-will-best-anti-th17-drugs-in-autoimmune-disorders-a17Emerging Company ProfileNumab's bispecific mAb program has the potential to provide greater efficacy by eliminating T cells vs. approaches that block T cell differentiation.Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-05-27/numab-safely-killing-t-cells-sidebar-numab-ag-corporate-profile-11http://www.biocentury.com/biotech-pharma-news/emergingcompany/2013-05-27/numab-safely-killing-t-cells-sidebar-numab-ag-corporate-profile-11Emerging Company ProfileNumab: Safely Killing T Cells Numab AG Waedensil, Switzerland Technology: Mono- and bispecific antibody fragment-based discovery Disease focus: Autoimmune Clinical status: Discovery Founded: 2011 by David Urech,…Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/biotech-investor-banker-and-analyst-personnel-changes-a21dhttp://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/biotech-investor-banker-and-analyst-personnel-changes-a21dFinanceEbb & Flow Banker tracks Andrew Gitkin joined Piper Jaffray as a managing director and head of West Coast biotechnology investment banking. He was a senior investment banker in the life sciences group at Moelis & Co…Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/demand-disequilibrium-figure-clinical-rationing-06http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/demand-disequilibrium-figure-clinical-rationing-06FinanceDemand disequilibrium Clinical rationing Europe's private and public biotechs in the clinic both raised more money in 2012 vs. 2011. Of the $1.2 billion raised by private biotechs in 2012, $806.3 million, or 66%, …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/demand-disequilibrium-figure-private-demand-09http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/demand-disequilibrium-figure-private-demand-09FinanceDemand disequilibrium Private demand Private European biotechs in the clinic and beyond will need an estimated $4.54 billion to support operations to the end of 2015, compared with a three-year estimate of $4.59 …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/demand-disequilibrium-figure-public-demand-08http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/demand-disequilibrium-figure-public-demand-08FinanceDemand disequilibrium Public demand Public European biotechs in the clinic and beyond, but have not yet reached a profit, will need an estimated $906.5 million to support operations to the end of 2015. This compares…Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/demand-disequilibrium-table-new-eu-funds-07http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/demand-disequilibrium-table-new-eu-funds-07FinanceDemand disequilibrium New EU funds Since the start of 2012, at least 19 funds with a focus on life science investing in Europe have raised a total of more than $2.5 billion. (A) Fund was closed in 2010, but was re-…Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/ebb-and-flow-figure-money-raised-in-2013-13http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/ebb-and-flow-figure-money-raised-in-2013-13FinanceAutologous monetization Money Raised in 2013 Last week, the biotech industry raised $1,631 million, bringing to $11.2 billion the total raised year-to-date. In 2012, a total of $36.2 billion was raised, including $…Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/european-investors-demand-biotechs-focus-on-product-reimbursement-profile-a1http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/european-investors-demand-biotechs-focus-on-product-reimbursement-profile-a1FinanceBioCentury's 11th European Iceberg survey finds investors pushing companies to adapt to the new healthcare ecosystem by preparing assets to meet the needs of both payers and regulators.Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/ipo-news-flow-suggests-biotech-window-has-opened-at-last-a18http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/ipo-news-flow-suggests-biotech-window-has-opened-at-last-a18FinanceLast week's flurry of IPO activity, including the largest offering to close since 2011, suggests the biotech new offerings window has opened at last, at least in the U.S.Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/lps-flock-to-athyriums-structured-capital-fund-for-life-scienceshealthcare-a21ahttp://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/lps-flock-to-athyriums-structured-capital-fund-for-life-scienceshealthcare-a21aFinanceEbb & Flow Autologous monetization Figure: Money Raised in 2013 While the equity markets have clear appetite for new biotech paper, the oversubscribed Athyrium Opportunities Fund L.P. shows investors are not …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/novel-biology-chemistry-behind-big-a-round-for-oncogene-play-effector-a21chttp://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/novel-biology-chemistry-behind-big-a-round-for-oncogene-play-effector-a21cFinanceEbb & Flow Targeting translation Effector Therapeutics Inc. recorded the second-largest series A round thus far this year, driven by novel biology and founders and management with a track record of exits. The …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/regulatory-clinical-and-other-milestones-a21ehttp://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/regulatory-clinical-and-other-milestones-a21eFinanceEbb & Flow Regulatory milestones Biogen Idec Inc. (NASDAQ:BIIB) was up $8.39 to $235.24 last week after submitting a BLA to FDA for Plegridy peginterferon beta-1a (BIIB017) to treat relapsing forms of multiple …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/results-of-biocenturys-11th-survey-of-funding-needs-for-european-biotechs-a8http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/results-of-biocenturys-11th-survey-of-funding-needs-for-european-biotechs-a8FinanceBioCentury's 11th European Iceberg survey sees funding demand continue to fall for a shrinking number public clinical-stage biotechs in Europe, while underlying demand by a growing cadre of venture plays continues to …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/value-reality-check-figure-capital-rationing-04http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/value-reality-check-figure-capital-rationing-04FinanceValue reality check Capital rationing The average venture raised per European company was $12.8 million in 2012 vs. $11.8 million in 2011. The 2012 number includes a $150 million series B round by NovImmune S.A. …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/value-reality-check-figure-eu-vs-us-private-raised-03http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/value-reality-check-figure-eu-vs-us-private-raised-03FinanceValue reality check EU vs. U.S. private raised Private European biotechs raised $1.2 billion in 2012, the same amount as in 2011. In the U.S., private companies saw a 28% increase in venture money raised to $4.7 …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/value-reality-check-figure-eu-vs-us-public-raised-01http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/value-reality-check-figure-eu-vs-us-public-raised-01FinanceValue reality check EU vs. U.S. public raised Excluding debt, the top figure shows public biotechs in Europe increased their fundraising by 24% to $1.2 billion from 2011 vs. a 35% increase in the U.S. to $8.3 …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/value-reality-check-figure-europes-total-demand-05http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/value-reality-check-figure-europes-total-demand-05FinanceDemand disequilibrium Europe's total demand BioCentury projects that private and public European biotech companies with compounds in the clinic and beyond will need $5.5 billion over the next three years to keep …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/value-reality-check-figure-global-competition-for-capital-02http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/value-reality-check-figure-global-competition-for-capital-02FinanceValue reality check Global competition for capital The total money raised by European and U.S. biotechs declined in 2012, as 2011 and 2010 were bulked up by a series of large debt deals. The funding figure actually …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/waxing-window-table-ipo-queue-12http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/waxing-window-table-ipo-queue-12FinanceWaxing window IPO queue At least 18 companies have proposed IPOs, of which 11 were announced since the start of April. Unless noted, companies are seeking to list on NASDAQ. Most recent filing at top. (A) Status at …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/with-48m-karyopharm-looks-to-advance-cancer-compound-through-pivotal-trials-a21bhttp://www.biocentury.com/biotech-pharma-news/finance/2013-05-27/with-48m-karyopharm-looks-to-advance-cancer-compound-through-pivotal-trials-a21bFinanceEbb & Flow Stop SINE Karyopharm Therapeutics Inc. hopes to advance lead compound KPT-330 through pivotal trials for at least two cancer indications with funds from last week's $48.2 million series B round. An …Mon, 27 May 2013 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2013-05-27/elan-shareholders-must-choose-between-managements-deal-flurry-or-64b-payout-a13http://www.biocentury.com/biotech-pharma-news/strategy/2013-05-27/elan-shareholders-must-choose-between-managements-deal-flurry-or-64b-payout-a13StrategyIf Elan is able to fend off Royalty Pharma's latest offer at a June shareholder meeting, the company will reinvent itself as a royalty-backed business with a small late-stage pipeline.Mon, 27 May 2013 00:00:00 -0700